← Back to Search

Antiviral Agent

EDP-938 and tacrolimus interaction (Part 1) for Respiratory Syncytial Virus

Phase 1
Waitlist Available
Research Sponsored by Enanta Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 34 days
Awards & highlights

Summary

This study is evaluating whether a drug may have negative impacts for individuals with heart disease.

Eligible Conditions
  • Respiratory Syncytial Virus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 34 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 34 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC of dabigatran with and without coadministration with EDP-938
AUC of midazolam with and without coadministration with EDP-938
AUC of rosuvastatin with and without coadministration with EDP-938
+5 more
Secondary outcome measures
Safety measured by adverse events

Trial Design

4Treatment groups
Experimental Treatment
Group I: EDP-938 and tacrolimus interaction (Part 1)Experimental Treatment2 Interventions
Group II: EDP-938 and rosuvastatin interaction (Part 3)Experimental Treatment2 Interventions
Group III: EDP-938 and midazolam interaction (Part 4)Experimental Treatment2 Interventions
Group IV: EDP-938 and dabigatran interaction (Part 2)Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rosuvastatin
FDA approved
EDP-938
2021
Completed Phase 2
~420
Midazolam
FDA approved
Tacrolimus
FDA approved
Dabigatran
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Enanta PharmaceuticalsLead Sponsor
33 Previous Clinical Trials
2,259 Total Patients Enrolled
Enanta Pharmaceuticals, IncLead Sponsor
39 Previous Clinical Trials
2,895 Total Patients Enrolled
Pharmaceutical Research AssociatesOTHER
17 Previous Clinical Trials
12,975 Total Patients Enrolled
~18 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top